We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
What's Next for Altria (MO) Stock After Kroger (KR), Walmart (WMT), and Other Retailers Abandon E-Cigarette Sales?
Read MoreHide Full Article
Supermarket giant Kroger (KR - Free Report) became the latest retailer to discontinue the sale of electronic cigarettes amid regulatory scrutiny. Kroger joins rival supermarket giant Walmart (WMT - Free Report) and retail drug store chain Rite Aid in the suspension of electronic cigarette sales.
The vaping industry has come under heavy regulatory scrutiny recently after The Centers for Disease Control and Prevention has identified at least 19 vaping-related reported deaths and 1,080 probable cases across 48 states and the U.S. Virgin Islands. The news of Kroger’s decision comes on the heels of published research by New York University that further links vaping to harmful bodily effects.
NYU Study
Researchers at New York University conducted a study looking into the effects of vaping on mice and concluded that electronic cigarette vapor containing nicotine causes lung cancer and potentially bladder cancer in mice. The findings from the study has the researchers concluding that vaping is likely “very harmful” to humans as well. Out of 40 mice exposed to e-cigarette vapor with nicotine over 54 weeks, 22.5% developed lung cancer and 57.5% developed precancerous lesions on the bladder.
None of the 20 mice exposed to e-cigarette smoke without nicotine developed cancer over the four years they studied the mice. The NYU study isn’t the first to possibly link e-cigarette use with cancer. A February study by the University of Southern California found that e-cigarette users developed some of the same molecular changes in oral tissue that cause cancer in cigarette smokers.
What Does This Mean for Altria?
Back in late December, tobacco company Altria (MO - Free Report) , bought 35% of popular e-cigarette manufacturer, Juul, for $12.8 billion. The purchase was "by far the biggest investment ever in a U.S. venture-backed company" According to Wells Fargo (WFC - Free Report) , and the deal valued Juul Labs at $38 billion.
The decision to invest and ride the coattails of one of the most dominant vaping companies is now going up in flames. The FDA has called teen use of e-cigarettes an “epidemic” which has prompted the Trump administration to call for the federal ban of flavored e-cigarettes. Flavored pods represent 80% of Juul's revenue.
Large investors are now looking to dump their positions in Juul whose lost a third of its private market value and announced that it was firing 3,900 employees as it restructures its business. The investment has weighed on Altria's balance sheet as merger talks between Altria and international tobacco giant Phillip Morris (PM - Free Report) fell through as the two companies couldn’t come to an agreement and fingers point towards Altria’s investment in Juul as a main reason talks weren’t successful.
In late September, Juul CEO, Kevin Burns, resigned from his position and former Altria executive, K.C. Crosthwaite, stepped in. Crosthwaite was the former chief growth officer of Altria.
Now that Altria has one of its former executives at the helm, the company can try to salvage the large investment it made in Juul Labs. While it remains a separate business from Altria, Juul labs has aligned itself with the tobacco giant. Altria has decades of experience in dealing with regulators and marketing themselves appropriately which can help it restructure the battered Juul Labs.
Earnings Outlook
Our current quarter consensus estimates have Altria’s top line remaining flat at $5.29 billion while earnings come in at $1.14 per share for a 5.56% jump. Looking ahead to the company’s full fiscal year, estimates forecast net revenue to pop 0.41% to $19.71 billion and earnings to gain 5.01% to $4.19 per share. Altria shares are down 14.4% in 2019 thus far and the stock sports a Zacks Rank #3 (Hold).
Wall Street’s Next Amazon
Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time. It’s a once-in-a-generation opportunity to invest in pure genius.
Image: Bigstock
What's Next for Altria (MO) Stock After Kroger (KR), Walmart (WMT), and Other Retailers Abandon E-Cigarette Sales?
Supermarket giant Kroger (KR - Free Report) became the latest retailer to discontinue the sale of electronic cigarettes amid regulatory scrutiny. Kroger joins rival supermarket giant Walmart (WMT - Free Report) and retail drug store chain Rite Aid in the suspension of electronic cigarette sales.
The vaping industry has come under heavy regulatory scrutiny recently after The Centers for Disease Control and Prevention has identified at least 19 vaping-related reported deaths and 1,080 probable cases across 48 states and the U.S. Virgin Islands. The news of Kroger’s decision comes on the heels of published research by New York University that further links vaping to harmful bodily effects.
NYU Study
Researchers at New York University conducted a study looking into the effects of vaping on mice and concluded that electronic cigarette vapor containing nicotine causes lung cancer and potentially bladder cancer in mice. The findings from the study has the researchers concluding that vaping is likely “very harmful” to humans as well. Out of 40 mice exposed to e-cigarette vapor with nicotine over 54 weeks, 22.5% developed lung cancer and 57.5% developed precancerous lesions on the bladder.
None of the 20 mice exposed to e-cigarette smoke without nicotine developed cancer over the four years they studied the mice. The NYU study isn’t the first to possibly link e-cigarette use with cancer. A February study by the University of Southern California found that e-cigarette users developed some of the same molecular changes in oral tissue that cause cancer in cigarette smokers.
What Does This Mean for Altria?
Back in late December, tobacco company Altria (MO - Free Report) , bought 35% of popular e-cigarette manufacturer, Juul, for $12.8 billion. The purchase was "by far the biggest investment ever in a U.S. venture-backed company" According to Wells Fargo (WFC - Free Report) , and the deal valued Juul Labs at $38 billion.
The decision to invest and ride the coattails of one of the most dominant vaping companies is now going up in flames. The FDA has called teen use of e-cigarettes an “epidemic” which has prompted the Trump administration to call for the federal ban of flavored e-cigarettes. Flavored pods represent 80% of Juul's revenue.
Large investors are now looking to dump their positions in Juul whose lost a third of its private market value and announced that it was firing 3,900 employees as it restructures its business. The investment has weighed on Altria's balance sheet as merger talks between Altria and international tobacco giant Phillip Morris (PM - Free Report) fell through as the two companies couldn’t come to an agreement and fingers point towards Altria’s investment in Juul as a main reason talks weren’t successful.
In late September, Juul CEO, Kevin Burns, resigned from his position and former Altria executive, K.C. Crosthwaite, stepped in. Crosthwaite was the former chief growth officer of Altria.
Now that Altria has one of its former executives at the helm, the company can try to salvage the large investment it made in Juul Labs. While it remains a separate business from Altria, Juul labs has aligned itself with the tobacco giant. Altria has decades of experience in dealing with regulators and marketing themselves appropriately which can help it restructure the battered Juul Labs.
Earnings Outlook
Our current quarter consensus estimates have Altria’s top line remaining flat at $5.29 billion while earnings come in at $1.14 per share for a 5.56% jump. Looking ahead to the company’s full fiscal year, estimates forecast net revenue to pop 0.41% to $19.71 billion and earnings to gain 5.01% to $4.19 per share. Altria shares are down 14.4% in 2019 thus far and the stock sports a Zacks Rank #3 (Hold).
Wall Street’s Next Amazon
Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time. It’s a once-in-a-generation opportunity to invest in pure genius.
Click for details >>